Chronic infections with the hepatitis B virus (HBV) and high-risk human papillomaviruses (HPVs) are important risk factors for hepatocellular carcinoma (HCC) and cervical cancer (CC), respectively. HBV and HPV are DNA viruses that almost invariably integrate into the host genome in invasive tumors. The viral integration sites occur throughout the genome, leading to the presumption that there are no preferred sites of integration. A number of viral integrations have been shown to occur within the vicinity of important cancer-related genes. In studies of HBV-induced HCC and HPV-induced CC, we have identified two HBV and three HPV integrations into the human telomerase reverse transcriptase (hTERT) gene. Detailed characterization of the integrations revealed that four integrations occurred within the hTERT promoter and upstream region and the fifth integration occurred in intron 3 of the hTERT gene. None of the integrations altered the hTERT coding sequence and all resulted in juxtaposition of viral enhancers near hTERT, with potential activation of hTERT expression. Our work supports the hypothesis that the sites of oncogenic viral integration are nonrandom and that genes at the sites of viral integration may play important roles in carcinogenesis.
Introduction
The hepatitis B virus (HBV) and human papillomavirus (HPV) are tissue-specific DNA viruses that infect hepatocytes and basal squamous epithelial cells, respectively. Both viruses frequently integrate into the human host genome. Chronic HBV infections are associated with the development of hepatocellular carcinoma (HCC) and chronic HPV infections with the development of cervical cancer (CC) and squamous cell carcinoma of the head and neck (SCCHN). In each case, integration of the virus into the host genome is associated with the generation of novel fusion transcripts and local genomic instability, resulting in secondary deletions, rearrangements, duplications, or inversions of host or viral genomic sequences. Both viruses also encode proteins with oncogenic activity, particularly the X and preS gene products in the case of HBV and the E6 and E7 oncoproteins of HPV. These viral oncoproteins act by transactivating genes that regulate cellular growth. The relative contributions of viral integration-induced genomic changes and viral oncoprotein action to the development of virus-induced cancers have not been completely elucidated.
A number of HBV and HPV integrations have been shown to occur into or adjacent to genes that have important roles in oncogenesis. For HBV, these genes include the retinoic acid receptor beta (Dejean et al., 1986; Benbrook et al., 1988; Dejean and de The, 1990; Garcia et al., 1993) , cyclin A2 (Wang et al., 1990 (Wang et al., , 1992 Berasain et al., 1998) , SERCA1 (Chami et al., 2000; Gozuacik et al., 2001) , nuclear matrix protein p84 (Gozuacik et al., 2001) , thyroid hormone receptorassociated protein-150 alpha (Gozuacik et al., 2001) , minichromosome maintenance protein 8 (Gozuacik et al., 2001) , and hTERT genes (Kekule et al., 1990; Gozuacik et al., 2001) ; for HPV, they include the N-and C-Myc family members (Sastre-Garau et al., 2000), APM-1 (Reuter et al., 1998) , JunB (Choo et al., 1995) , FHIT (Wilke et al., 1996) , and Notch1 genes (Thorland et al., 2003) .
The mechanism of integration of DNA viruses into host tissues, the mechanism of generation of local genomic instability at the site of viral integration, and the role of viral integration in carcinogenesis are not fully understood. Although earlier studies of viral integration sites (using low-resolution methods such as Southern blotting and conventional cloning strategies) have led to the general conclusion that integration occurs into random sites within the genome (Matsubara and Tokino, 1990; Brechot et al., 2000) , more recent studies have suggested that oncogenic DNA viruses such as HBV and HPV preferentially integrate into common chromosomal fragile site regions (Thorland et al., 2000 (Thorland et al., , 2003 or near nuclear matrix attachment regions (Shera et al., 2001) .
In 80% or more of liver cancers induced by the HBVrelated woodchuck hepatitis virus (WHV), the virus integrates into or adjacent to the c-Myc, N-Myc1, or NMyc2 oncogenes (Hsu et al., 1988; Fourel et al., 1990; Buendia, 1992) . Such high rates of preferential integration have not been shown for any human DNA viruses, but this finding provides support for the hypothesis that viral integrations into specific genomic regions provide a growth advantage to a clonal population of proliferating cells that accumulates additional mutations, leading to the development of cancer. Thus, although the integration sites of viral DNA in benign liver or cervical epithelium may be randomly scattered throughout the genome, this hypothesis predicts that integrations in virus-induced cancers will be found at sites that conferred a survival or growth advantage on the affected cells. To test this hypothesis, we have developed strategies for cloning, sequencing, and analysis of the viral integration sites of HBV-induced HCCs and HPV-induced CCs.
In this paper, we report the cloning and detailed characterization of viral integrations into or adjacent to the human telomerase reverse transcriptase (hTERT) gene in a primary HCC, the HCC cell line SNU449, and three primary CCs. HBV integration has been shown to occur into the hTERT gene promoter in the huH-4 human HCC-derived cell line (Kekule et al., 1990; Horikawa et al., 1999) and into the hTERT gene in a primary HCC (Gozuacik et al., 2001) . Taken together with a recent report demonstrating cis-activation of the hTERT promoter by integrated HBV sequences in the huH-4 cell line (Horikawa and Barrett, 2001) , these results strongly suggest that integration of oncogenic DNA viruses such as HBV and HPV into the region of the hTERT gene may lead to the activation of hTERT transcription, telomerase activation, cellular immortalization, and predisposition to carcinogenesis.
Materials and methods

Samples
Eight HBV-positive HCC samples and matched adjacent benign liver samples were obtained during surgical resections at Mayo Clinic between 1991 and 2001. HPV16-positive CC samples were from The Chinese University of Hong Kong, and HPV18-positive CC samples were from the Mayo Clinic. The samples were frozen in liquid nitrogen and stored at À801C. Five HBV-positive HCC tumor cell lines (SNU387, SNU398, SNU423, SNU449, and SNU475) were obtained from the American Type Culture Collection (ATCC). The Mayo Clinic Institutional Review Board approved the study.
Restriction site PCR (RS-PCR)
RS-PCR is used to amplify DNA sequences when only one portion of the target sequence is known (Figure 1) (Sarkar et al., 1993; Weber et al., 1998; Thorland et al., 2000) . Viral integration leads to the juxtaposition of viral sequences adjacent to the human genomic sequence. In the RS-PCR procedure, a set of nested primers specific to the viral genome is defined. The HPV16-specific primers used were from Thorland et al. (2000) . The HPV18-specific primers used are shown in Table 1 and the HBV-specific primers in Table 2 . To create a PCR product, a partially degenerate primer is designed to amplify unknown sequences immediately adjacent to the site of viral integration. This restriction site oligonucleotide primer (RSO primer) incorporates (from 5 0 to 3 0 ) a T7 RNA polymerase promoter recognition site, 10 random nucleotides, and six bases specific for a chosen restriction endonuclease site (Table 3) . First-round RS-PCR is performed at the permissive reannealing temperature of 451C, followed by a nested second-round PCR performed with a more stringent reannealing temperature of 551C. Six RSOs were used that were specific for the restriction enzymes BamHI, EcoRI, NdeI, XbaI, Sau3AI, and TaqI. In all, 2 pmol of each virus-specific primer and 20 pmol of the RSO primer were combined with 100 ng of cell line or tumor DNA, 1 Â PCR buffer (Roche Diagnostics, Indianapolis, IN, USA) containing 1.5 mm MgCl 2 , 200 mm deoxynucleotide triphosphates, and 0.5 U of Expand Hi-Fi Taq Polymerase (Roche, Indianapolis, IN, USA) in a 20 ml reaction. After denaturation for 2 min at 941C, cycles of 30 s at 941C, 30 s at 451C (first round of PCR) or 551C (nested PCR), and 3 min at 681C were performed for 10 cycles, followed by 30 s at 941C, 30 s at 451C (first round of PCR) or 551C (nested PCR), and 3 min þ 20 s per cycle at 681C for 25 cycles, and finally 10 min at 721C. A volume of 1 ml of the product from the first round of RS-PCR was used as template for the nested PCR. An aliquot of the second-round nested PCR was separated on a 2.0% agarose gel. For HBV samples, the RS-PCR products were cloned into the pGEM-T Easy plasmid vector (Promega, Madison, WI, USA) prior to sequencing. For HPV16 and HPV18 samples, reactions that gave discernible PCR products were directly sequenced. The third internal virus-specific primer was used for sequencing. Sequencing was performed by the Mayo Clinic Molecular Biology Core Facility.
Long-range PCR
After identification of one viral-host DNA junction, additional long-range PCR experiments were performed with the HCC and CC DNA samples to clone the second viral-host DNA junction and to completely sequence the integrated viral DNA. Long-range PCR was performed using the Gene Amp XL PCR kit (Applied Biosystems, Foster City, CA, USA).
Real-time RT-PCR
hTERT mRNA expression was measured in a short-term human keratinocyte (Ker) cell culture, the HeLa CC cell line, two primary CCs, MC11 and MC34, the SNU449 HCC cell line, three primary HCCs, T89, T32, and T79, and their matched adjacent benign liver tissues, B89, B32, and B79. RNA was not available for CCs HK1 or HK2. Reverse transcription of DNase-treated RNA was performed with M-MLV RT (Invitrogen, Carlsbad, CA, USA). Samples MC11, SNU449, and T89 each have a single viral integration at or near the hTERT locus. Samples HeLa, MC34, T32, and T79 are tumors without a viral integration near hTERT. Primers used for hTERT were hTERT-F 5 0 -GGTGGAT-GATTTCTTGT-3 0 and hTERT-R 5 0 -GTGAAACCTG-TACGCC-3 0 ; primers for b-actin were b-actin-
Real-time RT-PCR was performed on the LightCyclert thermocycler (Roche). Each 20 ml reaction contained 1 ml of cDNA, 20 mm Tris-HCl, 50 mm KCl, 4.0 mm MgCl 2 , 0.05% BSA, 0.6 ml of a 10 Â dilution of Sybr Green I gel stain (Roche), 0.5 mm of each primer, 1.0 U of Platinum Taq DNA polymerase (Invitrogen), and 200 mm each of dGTP, dATP, dCTP, and TTP. After denaturation for 1 min at 951C, 38 cycles of amplification proceeded as follows: 951C for 0 s, 601C for 16 s, and 721C for 20 s. The temperature transition rate was set to 201C/s. Fluorescent signal was detected at 881C using the singleacquisition mode following each cycle of amplification. Standard curves for hTERT and b-actin, used to calculate relative gene expression, were constructed using serial dilutions of cDNA with high levels of both mRNAs.
Results
Integrations of HPV16 and HPV18 DNA into the hTERT gene in CC tumors MC11, HK1, and HK2
We used RS-PCR to screen 75 HPV16-and 34 HPV18-positive cervical tumors obtained from the Mayo Clinic and The Chinese University of Hong Kong (Figure 1 ). For each genomic DNA sample, 40 HPV18 and 32 HPV16 primary RS-PCR reactions were performed (using every possible combination of the four RSO primers with BamHI, EcoRI, NdeI, and XbaI restriction sites and the 10 HPV18-or eight HPV16-specific primers). This analysis identified two HPV16-positive cervical tumors and one HPV18-positive cervical tumor (Table 1) and RS-BamHI. Even lanes 2-16, 35, and 36 used the same HPV18 primers and RS-EcoRI. Odd lanes 17-31, 37, and 38 used the same HPV18 primers and RS-XbaI. Even lanes 18-32, 39, and 40 used the same HPV18 primers and RS-NdeI. Sequencing was performed with the appropriate nested primer (Table 1) . Lanes 7, 16, 24, and 34 (*) were positive for both HPV-18 and hTERT flanking sequences. The remaining sequenced lanes proved to be all HPV-18 sequence with integrations into the hTERT gene. Long-range PCR was then performed to isolate the second viralhost DNA junction (Figure 2 ). The first cervical tumor with an hTERT integration was tumor MC11, obtained from the Mayo Clinic. This tumor contained an integration of HPV18 into the hTERT gene (Figure 3a) . The proximal viral-host junction identified in MC11 was at nucleotide 16102 of GenBank sequence AY007685, approximately 8.3 kb proximal to the hTERT transcription start site (located at nucleotide 24442 of AY007685) (Leem et al., 2002) . We rescued the distal end of this integration using longrange PCR and sequenced the integrated HPV18 sequence. The integration was associated with a deletion of HPV18 sequences from nucleotides 4129-6143. In addition, this integration resulted in the deletion of 1183 nucleotides of hTERT upstream sequence (nucleotides 16103-17184 of GenBank sequence AY007685). Long-range PCR across the integration suggests that this represents a single integration of HPV into the hTERT upstream sequence as depicted in Figures 2  and 3a .
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The third cervical tumor with an hTERT integration was also an HPV16-positive cervical tumor obtained from Hong Kong, designated HK2. This integration also occurred into the hTERT upstream sequence approximately 2.8 kb upstream of the transcription start site (at position 21593 in the hTERT genomic sequence, accession number AY007685) (Figure 3c ). We have not cloned the downstream viral-human junction in this tumor sample.
Integration of HBV DNA into the hTERT gene in HCC tumor T89 and cell line SNU449
RS-PCR was used to screen genomic DNA from eight HBV-positive HCC tumors (T29, T31, T40, T47, T60, T73, T87, and T89) and five HBV-positive HCC cell lines (SNU387, SNU398, SNU423, SNU449, and SNU475). For each genomic DNA sample, 32 primary RS-PCR reactions were performed (using every possible combination of the four RSO primers with BamHI, EcoRI, Sau3AI, and TaqI restriction sites and the eight HBV-specific primers).
For HCC tumor T89, analysis of the initial RS-PCR product containing the HBV/cellular DNA junction sequence revealed 78 bp of HBV sequence (100% identity match to position 2318-2396 of the HBV genome, sequence accession number AF068756) joined to 557 bp of human DNA corresponding to the upstream promoter region of hTERT (position 21043-21600 in the hTERT genomic sequence accession number AY007685) (Figure 3d ). The proximal viralhuman junction of this integration was therefore only seven bases from the proximal viral-human junction of the HPV integration into tumor HK2 (position 21593 in AY007685). Additional analysis of the integration was performed using long-range PCR with primers designed from the cloned HBV integrated sequence fragment and hTERT exons 1-5 in an attempt to characterize the entire integrated HBV sequence. Using this strategy, a 2.5 kb PCR fragment was amplified and sequenced. Analysis of the sequence of the entire HBV integration with flanking human host sequences revealed a 2285 bp deletion of the hTERT promoter region at the site of integration (position 21601-23885 of the hTERT genomic sequence accession number AY007685). The integrated HBV sequence was HBV genotype C (highest homology in GenBank to HBV Thai isolate Th44, sequence accession number AF068756) and had an internal deletion of 863 bp (HBV nucleotides 2898-3215 and 1-545).
In the HCC cell line SNU449, the 1452 bp initial RS-PCR product containing the HBV/cellular DNA junction sequence had 815 bp of HBV sequence (98% identity match to positions 1451-1805 and 1216-760 of the HBV genome, sequence accession number AF330110) joined to 637 bp of sequence from intron 3 of the hTERT gene (position 35782-36418 in the hTERT genomic sequence accession number AY007685) (Figure 3e ). Long-range PCR with primers designed from the cloned HBV integrated sequence fragment and hTERT exons 4 and 5 resulted in amplification of a 3.1 kb PCR fragment. Analysis of the sequence of the entire HBV integration with flanking human host sequences revealed a 5 bp deletion of hTERT intron 3 (position 37133-37137 of the hTERT genomic sequence, accession number AY007685). The integrated HBV sequence was a fusion of two HBV DNA fragments in opposite orientations, with nucleotides 1451-1805 attached to nucleotides 1216-436. Nucleotides 1806-3215, 1-435, and 1217-1450 of the HBV genome were therefore deleted. The integrated HBV sequence in HCC cell line SNU449 was also genotype C, with the highest homology in GenBank to HBV strain T-1858, sequence accession number AF330110.
hTERT is upregulated in CC tumor MC11, HCC tumor T89, and HCC cell line SNU449
Telomerase is activated in human immortal cell lines and tumor tissues, but not in quiescent cells. hTERT expression is the limiting factor in telomerase activation, and upregulation of hTERT with consequent telomerase activation is thought to be a critical step in malignant transformation, occurring in 80-90% of all malignancies. Since HPV and HBV integrations into the hTERT gene were found in tumors MC11 and T89 and cell line SNU449, real-time RT-PCR was used to evaluate the expression level of hTERT to determine whether the integrations were associated with upregulation of hTERT expression. hTERT mRNA expression was upregulated in the MC11 CC tumor as compared with a human keratinocyte culture (Ker) as well as in both HCC tumor T89 and HCC cell line SNU 449 as compared to benign liver (Ben) (Figure 4) . Since activated lymphocytes have high levels of hTERT expression and some tumors have high levels of lymphocyte infiltration, the histology of each sample was reviewed by a pathologist (LJB). None of the tumors had significant levels of lymphocyte infiltration (data not shown).
Discussion
The prevailing model for the role of integration of DNA viruses in carcinogenesis is that viral integration is a random event (Matsubara and Tokino, 1990; Brechot et al., 2000) . It is presumed that DNA sequences that are more unstable or fragile may be more susceptible to breakage and may promote viral integration events, but that the predominant role of the viral integration event is to initiate conditions of overall genomic instability that ultimately result in oncogene activation and tumor suppressor inactivation, leading to the development of cancer. Integration of HBV and HPV are frequent events in the development of HCC and CC tumors, respectively. Most tumors contain a single HBV or HPV integration. HBV integration usually involves a region of the virus that contains two direct repeat sequences, DR1 and DR2. HPV integration results in disruption of the E2 gene of HPV in 20/22 junctions characterized by our group, underscoring the importance of the disruption of this gene in HPV16 integration-related events in cervical carcinogenesis (Thorland et al., 2003) . These results are consistent with the observation that cells with integrated HPV have a selective growth advantage and that E2 damage is associated with a poor prognosis and shortened disease-free survival (Jeon et al., 1995; Vernon et al., 1997; Kalantari et al., 1998) . According to the current model, genomic instability resulting from viral Relative hTERT mRNA expression was determined by real-time RT-PCR using b-actin expression as the control. The samples were separated into two groups, CC and HCC. Relative hTERT expression in the HeLa CC cell line and two primary CCs, MC11 and MC34, was compared to that of short-term cultured human keratinocytes (Ker). hTERT expression levels in the HCC cell line SNU449 and three primary HCCs, T89, T32, and T79, each with their respective matched adjacent benign liver tissues, B89, B32, and B79, were compared to an average of the expression in the three benign liver tissues (Ben) from patients 89, 32, and 79. The results shown are the mean and standard error of three independent measurements. hTERT expression was significantly elevated in HeLa cells and CC MC11, as compared to HK cells (Pp0.05 for both, Student's t-test), in the SNU449 cell line as compared to average benign liver (Po0.001), and in two of the CCs, T89 and T32, as compared to matched benign liver (Po0. 01 and Po0.001, respectively) integration and enhanced expression of viral oncoproteins (X and preS for HBV, and E6 and E7 for HPV) are both procarcinogenic. According to this model, although regions in which multiple viral integrations occur may be inherently unstable, these regions and the associated genes do not contribute significantly to cancer development. Our data suggest that in a subset of HCC and CC tumors, the viral integration itself is a mutagenic event that acts in concert with the overexpression of viral oncoproteins to promote the development of cancer.
We have previously demonstrated that RS-PCR is an efficient method for isolating the sequences flanking the sites of HPV16 integration in cervical tumors (Thorland et al., 2000 (Thorland et al., , 2003 . In this study, we have utilized RS-PCR to rescue sequences flanking the sites of HBV integrations in HCCs, and of HPV16 and HPV18 integrations in CCs. We have identified multiple viral integrations into hTERT in both HCCs and CCs. However, integrations into the hTERT region were found in only one out of eight primary HCCs, one of five HCC cell lines, one of 34 HPV18-induced CCs and two of 75 HPV16-induced CCs. This suggests that other mechanisms besides viral integration are responsible for hTERT activation in the majority of HCCs and CCs.
Long-range PCR was used to fully characterize the resulting viral integrants in three of the five viral integrations (tumors MC11, T89, and cell line SNU449). This analysis showed that HBV and HPV integrations into the hTERT gene region are associated with small deletions of DNA sequences at the site of integration, which do not disrupt the hTERT coding sequence. These findings are very similar to those previously observed in the huH-4 human HCC cell line, in which HBV integration takes place into the promoter region of hTERT (Kekule et al., 1990) . In huH-4, the integrated HBV DNA contains the HBV enhancer sequence, which has been shown to be capable of trans-activating the hTERT promoter (Horikawa and Barrett, 2001) . Moreover, Gozuacik et al. (2001) recently reported HBV DNA integration upstream of the hTERT promoter in an HCC and demonstrated increased expression of hTERT protein in the tumor as compared to nontumorous adjacent benign tissue. HPV sequences also contain powerful promoter/enhancer sequences in the long control region, which is normally repressed by the E2 protein (Steger and Corbach, 1997; Kozuka et al., 2000) . Since the E2 gene is usually deleted in the HPV integrations found in CCs, the long control region is transcriptionally active, enhancing expression of the oncogenic E6 and E7 proteins.
Each of the fully characterized integrations resulted in the positioning of powerful viral enhancers next to fully functional hTERT alleles. Furthermore, since the HPV enhancer is located immediately adjacent to the E6 and E7 regions, which are almost always retained in CCs (Thorland et al., 2003) , it is probable that the two partially characterized HPV integrations also place the HPV enhancer upstream of the hTERT transcription start site. Both the HBV enhancer 1 sequence and the HPV long control region promoter/enhancer sequence have been shown to mediate IL-6-responsive transcriptional activation via the transcription factor STAT-3 (Smola-Hess et al., 2001; Waris and Siddiqui, 2002) . Since both HBV and HPV infections lead to chronic inflammation and cytokine release, it is tempting to speculate that cytokine activation may drive expression of potentially tumorigenic genes such as hTERT that are at the site of viral integrations, thus producing a causative link between inflammation and carcinogenesis.
In contrast to previous analyses of HBV and HPV integrations, in which large deletions of host genomic DNA were commonly found, deletions of relatively small size were found in association with the HBV and HPV integrations in the hTERT region. This finding may reflect a selection for viral integrations that do not extensively alter the genomic structure of this gene. In addition, many of the HPV integrations that are associated with large structural deletions occur within common fragile site regions (Wilke et al., 1996; Thorland et al., 2003) . The hTERT gene is not located within a fragile site, and may be more amenable to viral insertion without the production of large deletions.
Our results demonstrate that viral integrations into and around hTERT are observed in both HCCs and cervical tumors. The higher hTERT expression levels detected in the three tumors with hTERT integrations (MC11, T89, and SNU449) may be due to viral integration or to transformed cells overproducing hTERT, as is frequently observed in tumors. However, the observation that hTERT coding sequences remain intact in each of the five viral integrations argues that hTERT is the target of these integrations and that the integrations lead to increase in hTERT expression which, in concert with the effects of viral oncoproteins, results in cell transformation. We have initiated functional studies to determine the direct effects of these integrations on hTERT expression.
We therefore propose an alternative model for the role of viral integration in the development of cancer. This model is based upon the results described here showing real specificity of integration around hTERT, and our results analysing large numbers of HPV16 (Thorland et al., 2003) and HPV18 integrations in cervical tumors (M Ferber, unpublished observations) . We propose that the regions into which viral integrations occur may contain important genes that are altered by the viral integration event and that participate in carcinogenesis. The tumor phenotype may also be determined by the site of viral integration. We are currently investigating the relation between sites of viral integration and the clinical phenotype of the resulting tumor. 
